✦ LIBER ✦

421 A phase II trial of docetaxel in squamous cell cancer of the head and neck

✍ Scribed by M. Posner; A. Dreyfuss; C. Norris; R. Costello; R. Rossi; M. Poulin; J. Clark; P. Busse

Book ID: 116167174
Publisher: Elsevier Science
Year: 1995
Tongue: English
Weight: 158 KB
Volume: 31
Category: Article
ISSN: 0959-8049
DOI: 10.1016/0959-8049(95)95674-u

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II trial of deoxyspergualin in r

A phase II trial of deoxyspergualin in recurrent squamous cell head and neck cancer

✍ David G. Pfister; Dean Bajorin; Robert J. Motzer; Howard Scher; Carl Louison; Lo 📂 Article 📅 1993 🏛 Springer US 🌐 English ⚖ 269 KB

Phase I/II trial of weekly docetaxel and

Phase I/II trial of weekly docetaxel and concomitant radiotherapy for squamous cell carcinoma of the head and neck

✍ Masato Fujii; Mamoru Tsukuda; Bunsuke Satake; Akira Kubota; Akinori Kida; Naoyuk 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 428 KB

Phase II trial: concurrent radio-chemoth

Phase II trial: concurrent radio-chemotherapy with weekly docetaxel for advanced squamous cell carcinoma of head and neck

✍ A. Biete Solà; J. Marruecos Querol; F. A. Calvo Manuel; E. Verger Fransoy; À. Ro 📂 Article 📅 2007 🏛 Springer Milan 🌐 Spanish ⚖ 469 KB

A phase II study of docetaxel in patient

A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck

✍ Couteau, C; Chouaki, N; Leyvraz, S; Oulid-Aissa, D; Lebecq, A; Domenge, C; Groul 📂 Article 📅 1999 🏛 Nature Publishing Group 🌐 English ⚖ 63 KB

Phase II trial of VP16–213 in squamous c

Phase II trial of VP16–213 in squamous cell carcinoma of the head and neck

✍ Clerico, Mario; Bertetto, Oscar; Dongiovanni, Vincenzo; Calciati, Alessandro 📂 Article 📅 1987 🏛 Elsevier Science ⚖ 92 KB

A phase II study of mitoxantrone in adva

A phase II study of mitoxantrone in advanced squamous cell cancer of the head and neck

✍ H. Wheeler; R. L. Woods; J. Page; J. Levi 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 186 KB

Twenty patients with advanced squamous cell carcinomas (SCC) of the head and neck were entered into a phase II study of mitoxantrone at a dosage of either 12 mg/m2 or 14 mg/m2 given at 3 weekly intervals. None of the patients had received prior chemotherapy. One patient had a partial remission. Two